1. TransCelerate. Position paper: Risk-based monitoring methodology. 2013. http://www.transceleratebiopharmainc.com/wp-content/uploads/2013/10/TransCelerateRBM-Position-Paper-FINAL-30MAY2013.pdf. Accessed April 16, 2015.
2. Food and Drug Administration. Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. August 2013. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM269919.pdf. Accessed April 16, 2015.
3. Grimes I. Leveraging statistical tools when designing risk-based monitoring plans. Presented at: CBI’s Risk-Based Approaches to Clinical Investigations; April 11, 2012.
4. Burgess M. Less is more: risk-based monitoring of site performance. ICON Insight, Vol 13, May 2013. http://www.iconplc.com/icon-files/insight-newsletter/June13/lessismore.html. Accessed April 16, 2015.
5. Landray M. Clinical trials: rethinking how we ensure quality. Presented at: DIA/FDA webinar; July 22, 2013.